Literature DB >> 15944774

Expression of insulin-like growth factor-I receptor, estrogen receptor alpha, Bcl-2 and Bax proteins in human breast cancer.

Mariusz Koda1, Wojciech Przystupa, Katarzyna Jarzabek, Andrzej Wincewicz, Luiza Kanczuga-Koda, Jakub Tomaszewski, Mariola Sulkowska, Slawomir Wolczynski, Stanislaw Sulkowski.   

Abstract

Disturbance in expression of estrogen receptors together with changing influence of growth factor receptors and apoptosis associated proteins plays a role in breast cancer development and progression. However, immunohistochemical detection and relationships among these proteins were not often considered in relation to breast cancer and a few evaluations of expression provided mismatching results and conclusions. Consequently, we examined by immunohistochemistry the expression of the insulin-like growth factor-I receptor (IGF-IR), estrogen receptor alpha (ERalpha) and apoptosis-associated proteins, Bcl-2 and Bax, in human primary breast cancer, as well as analyzing the relationships among these proteins. The positive immunostaining for IGF-IR, ERalpha, Bcl-2 and Bax was noted in 56, 63.8, 82.8 and 50% of tumors, respectively. We observed that IGF-IR negatively correlated with ERalpha in the group of all tumors and in axillary node negative cancer (p<0.03, p<0.05, respectively), but not in the subgroup of node positive cancer. Expression of ERalpha correlated positively with Bcl-2 and negatively with Bax proteins (p<0.0001, p<0.05, respectively). We did not note significant relationships between IGF-IR and Bcl-2, or IGF-IR and Bax proteins. We found that increased Bax expression was associated with positive lymph node status, pT2 stage and G3 grade of tumors. Knowledge about alterations in the IGF-IR expression and relations of the receptor to other biological factors could help in our understanding of breast cancer biology and the importance of the IGF-IR in cancer progression as well as in effective management of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944774

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy.

Authors:  Luiza Kanczuga-Koda; Mariusz Koda; Jakub Tomaszewski; Katarzyna Jarzabek; Joanna Lotowska; Marek Baltaziak; Urszula Sulkowska; Maria Sobaniec-Lotowska; Stanisław Sulkowski
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

Review 2.  The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis.

Authors:  Robert A Jones; Roger A Moorehead
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-11       Impact factor: 2.673

3.  Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.

Authors:  S E Franks; C I Campbell; E F Barnett; M D Siwicky; J Livingstone; S Cory; R A Moorehead
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

Review 4.  The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.

Authors:  Arthur Adams; Aram S A van Brussel; Jeroen F Vermeulen; Willem P Th M Mali; Elsken van der Wall; Paul J van Diest; Sjoerd G Elias
Journal:  BMC Cancer       Date:  2013-11-10       Impact factor: 4.430

5.  Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice.

Authors:  Katrina L Watson; Roger A Moorehead
Journal:  BMC Cancer       Date:  2013-08-07       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.